Converting Furosemide 3 mg/hr Infusion to Bumetanide Boluses
For a continuous furosemide infusion of 3 mg/hr, convert to bumetanide 0.075 mg (75 mcg) IV bolus every hour, or more practically, 0.5 mg IV every 6-8 hours.
Conversion Rationale
The established potency ratio between furosemide and bumetanide is 40:1 1, 2. This ratio is consistently supported across FDA labeling and clinical research, meaning 1 mg of bumetanide equals approximately 40 mg of furosemide.
Calculation for Your Specific Case:
- Furosemide infusion: 3 mg/hr × 24 hours = 72 mg total daily dose
- Equivalent bumetanide dose: 72 mg ÷ 40 = 1.8 mg total daily dose
Practical Dosing Strategies
Option 1: Frequent Bolusing (Most Equivalent)
- 0.5 mg IV every 6-8 hours (2-3 times daily)
- This provides 1.5-2 mg daily, closely matching the continuous infusion effect
- Aligns with guideline-recommended bumetanide dosing intervals 3, 4
Option 2: Three Times Daily
- 0.5-1 mg IV three times daily
- Maximum single dose should not exceed 4-8 mg 4, 5
- More aggressive for resistant edema
Option 3: Continuous Bumetanide Infusion
- 0.5-2 mg/hour IV infusion (if continuous therapy preferred)
- For your case: approximately 0.075 mg/hour (75 mcg/hr)
- Requires ICU-level monitoring in many institutions 3
Important Clinical Considerations
Bumetanide advantages over furosemide:
- Superior oral bioavailability (80-90% vs 40-50% for furosemide) 6
- More predictable absorption, especially in edematous states 3, 7
- Potentially better response in renal insufficiency 8
- Lower ototoxicity risk 6, 9
Monitoring requirements:
- Daily weights, intake/output
- Electrolytes (especially potassium, magnesium) checked daily initially 3, 4
- Serum creatinine monitoring - mild increases (up to 30% baseline) during effective decongestion are common and acceptable 3
- Watch for contraction alkalosis with high doses 10
Common Pitfalls to Avoid
Underdosing: The 40:1 ratio is well-established; don't use more conservative ratios like 20:1 or 25:1 2, 11
Overlooking bioavailability: If transitioning to oral therapy, bumetanide maintains near 1:1 IV-to-oral equivalence, while furosemide requires doubling the oral dose 10, 1
Inadequate electrolyte replacement: Bumetanide causes similar potassium wasting to furosemide; maintain concurrent ACEI/ARB or aldosterone antagonist therapy 12, 7
Ignoring diuretic resistance: If response inadequate after 2-3 days, consider:
Evidence Quality Note
The 40:1 conversion ratio is supported by FDA labeling 1, multiple ACC/AHA guidelines 12, 3, 7, and validated in heart failure populations 2, 11. Recent 2024 data in acute decompensated heart failure suggests similar urine output between agents when dosed appropriately, though some studies indicate furosemide may require higher doses than the traditional 40:1 ratio predicts 11.